IgA 肾病患者的阿塞西普 (ORIGIN 3)
一项 IIb 期随机、双盲、安慰剂对照、剂量范围研究,以评估 Atacicept 在 IgA 肾病 (IGAN) 受试者中的疗效和安全性
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
研究概览
详细说明
This is a multi-part study comprising of the original Phase 2b study and the addition of a separate pivotal Phase 3 study.
After the completion of the primary results for the Ph 2b dose ranging study, the pivotal study will evaluate the efficacy and safety of atacicept compared to placebo in reducing proteinuria in subjects with IgAN and persistent proteinuria despite being on a maximally tolerated dose (MTD) of a RASi. Safety, eGFR, serum immunoglobulins and Gd-IgA1 will also be clinically assessed. The clinical study is comprised of a 104wk double-blind treatment period, followed by a 52wk open-label treatment period and a 26wk safety follow-up period. The UPCR primary endpoint will be assessed after the first 200 patients are randomized.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
California
-
Brisbane、California、美国、94005
- ORIGIN 3 Global Site Contact Information
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Must have the ability to understand and sign a written informed consent form
- Male or female of ≥18 years of age
- Total urine protein excretion ≥1.0 g per 24-hour or urine protein to creatinine ratio (UPCR) ≥1.0 mg/mg based on a 24-hour urine sample during the Screening Period
- Diagnosis of IgAN as demonstrated by renal biopsy conducted within 10 years
- eGFR ≥ 30 mL/min/1.73 m2, as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
- On a stable prescribed regimen of RAASi for at least 12 weeks that is at the maximum labeled or tolerated dose at Screening
- Systolic blood pressure ≤150 mmHg and diastolic blood pressure ≤90 mmHg
Key Exclusion Criteria:
- IgAN secondary to another condition (e.g., liver cirrhosis), or other causes of mesangial IgA deposition including IgA vasculitis (i.e., Henoch-Schonlein purpura), systemic lupus erythematosus (SLE), dermatitis herpetiformis, ankylosing spondylitis
- Total urine protein excretion ≥ 5g per 24-hour or urine protein to creatinine ratio (UPCR) ≥ 5 mg/mg based on a 24-hour urine sample during the Screening Period
- Evidence of rapidly progressive glomerulonephritis (loss of ≥ 50% of eGFR within 3 months of screening)
- Evidence of nephrotic syndrome within 6 months of screening (serum albumin <30g/L in association with UPCR >3.5 mg/mg
- Renal or other organ transplantation prior to, or expected during the study
- Concomitant chronic renal disease in addition to IgAN
- Uncontrolled diabetes, defined as hemoglobin-A1c (HbA1c) >7.5% at screening
- History of tuberculosis (TB), untreated latent TB infection (LTBI), or evidence of active TB determined by a positive Quantiferon test
- Participation in the Phase 2b (Parts A and B) study or any previous treatment with atacicept
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Atacicept Dose 150mg
Atacicept 150mg once weekly subcutaneous (SC) injections |
Once weekly subcutaneous (SC) injections by prefilled syringe
其他名称:
|
|
安慰剂比较:Placebo to match Atacicept (Part C/D)
Placebo to match Atacicept once weekly subcutaneous (SC) injection |
Once weekly subcutaneous (SC) injections by prefilled syringe |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage Change From Baseline in Urine Protein to Creatinine Ratio (UPCR)
大体时间:36 Weeks
|
Percentage reduction in UPCR was obtained from geometric mean ratios. The natural log-transformed ratio of UPCR to its baseline value was analyzed using a Mixed Model for Repeated Measures (MMRM), adjusted by baseline variables specified in the Statistical Analysis Plan (SAP), including data from baseline up to Week 36 during the Double-Blind period. |
36 Weeks
|
合作者和调查者
调查人员
- 研究主任:Eric Michael, MD、Senior Director, Clinical Development
出版物和有用的链接
一般刊物
- Barratt J, Barbour SJ, Brenner RM, Cooper K, Wei X, Eren N, Floege J, Jha V, Kim SG, Maes B, Phoon RKS, Singh H, Tesar V, Lafayette R; ORIGIN Phase 2b Investigators. Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy. J Am Soc Nephrol. 2025 Apr 1;36(4):679-687. doi: 10.1681/ASN.0000000541. Epub 2024 Oct 26.
- Barratt J, Brenner RM, Barbour SJ, Campbell KN, Doan T, Eren N, Floege J, Fordyce MW, Jha V, Khawaja Z, Kim BS, Liew A, Maes B, Pal A, Pecoits-Filho R, Phoon RKS, Rizk DV, Suzuki H, Tesar V, Trimarchi H, Wei X, Yu L, Zhang H, Lafayette R; ORIGIN Phase 3 Trial Investigators. Atacicept in IgA Nephropathy - Phase 3 Trial Final Efficacy Analysis. N Engl J Med. 2026 Oct 22. doi: 10.1056/NEJMoa2610103. Online ahead of print.
- Howie AJ, Lalayiannis AD. The Oxford Classification Should Remain the Gold Standard for Classification of IgA Nephropathy: CON. Kidney360. 2026 Oct 1;7(10):2382-2384. doi: 10.34067/KID.0000001083. Epub 2026 Feb 9. No abstract available.
- Barratt J, Chen K, Lafayette R. A plain language summary: long-term safety and effectiveness of atacicept in individuals with IgA nephropathy. Curr Med Res Opin. 2025 Dec;41(12):2287-2301. doi: 10.1080/03007995.2026.2615321. Epub 2026 Feb 1.
- Lafayette R, Barbour SJ, Brenner RM, Campbell KN, Doan T, Eren N, Floege J, Jha V, Kim BS, Liew A, Maes B, Pal A, Pecoits-Filho R, Phoon RKS, Rizk DV, Suzuki H, Tesar V, Trimarchi H, Wei X, Zhang H, Barratt J; ORIGIN Phase 3 Trial Investigators. A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy. N Engl J Med. 2026 Feb 12;394(7):647-657. doi: 10.1056/NEJMoa2510198. Epub 2025 Nov 6.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- VT-001-0050
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.